1 / 6

Program Support Update

Program Support Update. NHMRC Pneumovax23 Recommendations. Reference: 1. The Australian Immunisation Handbook, NHMRC. 9 th Edition, 2008, Chapter 3.15. History of the National Pneumococcal Vaccination Program for Older Australians ( > 65 years).

melodie-clark
Download Presentation

Program Support Update

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Program Support Update

  2. NHMRC Pneumovax23 Recommendations Reference: 1. The Australian Immunisation Handbook, NHMRC. 9th Edition, 2008, Chapter 3.15.

  3. History of the National Pneumococcal Vaccination Program for Older Australians (>65 years) Reference: 1. The Australian Immunisation Handbook, NHMRC. 9th Edition, 2008, Chapter 3.15.

  4. Pneumococcal Disease and the Elderly • Those aged 65 years or over are at higher risk of contracting pneumococcal disease compared with the rest of the population1 • The majority of deaths from pneumococcal disease occur in those 65 years and older1 • Pneumonia is the most common clinical presentation of pneumococcal disease in persons aged over 65 years, the case fatality rate exceeds 20%2 • The publicly funded Victorian pneumococcal vaccine program for the elderly, which commenced in 1998, resulted in a 36% reduction in IPD in over 65 year olds3 Reference: 1.Pneumococcal Disease, Australian Government Department of Health and Ageing, May 2009 <http://www.health.gov.au/internet/immunise/publishing.nsf/Content/immunise-pneumococcal>2. McIntyre, P.B. et al. (2000). Epidemiology of invasive pneumococcal disease in urban New South Wales . Medical Journal of Australia. 173 (Suppl), S22-6. 3. Andrews, R; Counahan, M; Hogg, G; McIntyre, P; 2004. ‘Effectiveness of a publicly funded pneumococcal vaccination program against invasive pneumococcal disease among the elderly in Victoria, Australia’. Vaccine; 23 (2004), p.132-138.

  5. Immunise 70+ Patients Before Winter • Up to 800,000 patients received their first dose of pneumococcal vaccine in 2005.1 • These patients now 70 years or older are due for their 5 year revaccination.2 • The uptake of the pneumococcal vaccine this year has been low, it is estimated that over 300,000 elderly Australians aged 70 years or older could still be due for their second dose1. • Possible reasons for low uptake: • Current method of recording an immunisation encounter is different to how it was recorded in 2005; e.g. entered in “patient notes” rather than recorded as an “immunisation” encounter • Consequently, software prompts and recalls can be ineffective in finding eligible patients • There is still time to identify and vaccinate all eligible patients • aged over 70 before winter. • Reference: 1. CSL Data on File. 2. NHMRC The Australian Immunisation Handbook. 9th Edition 2008, Chapter 3.15. • CSL Biotherapies Pty Ltd ABN 66 120 398 067, 45 Poplar Road, Parkville, 3052. 8597.

  6. PBS Information: This product is listed on the National Immunisation Program (NIP) Schedule and the PBS. Refer to the NIP and PBS Schedule. Please review product information before prescribing. Product Information is available on request. References are available on request. CSL Biotherapies Pty Ltd ABN 66 120 398 067, 45 Poplar Road, Parkville, 3052. Pneumovax23 is a registered trademark of Merck & Co. Inc, Whitehouse Station, NJ, USA. Thinking Australia is a registered trademark of CSL Biotherapies.

More Related